[1] Garcia-Tsao G. Terlipressin and Intravenous Albumin in Advanced Cirrhosis - Friend and Foe. N Engl J Med. 2021 Mar 4;384(9):869-871. 

[2] 张晓茹. 探究特利加压素、生长抑素和垂体后叶素三种血管活性药物治疗肝硬化食管胃底静脉曲张破裂出血的临床效果及经济性分析
[J]. 临床医学进展,2025,15(4): 2537-2543.

[3] 王秀辉,伍志,庄增礼,等. 垂体后叶素联合生长抑素治疗肝硬化上消化道出血临床观察
[J]. 中国药业,2022, 31(20):101-104. 

[4] 崔佳.内镜套扎联合垂体后叶素治疗肝硬化上消化道出血及对血流动力学及凝血功能的影响
[J].罕少疾病杂志,2025,32(05):98-100.

[5] Garcia-Tsao G, Abraldes JG, Rich NE, Wong VW. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review. Gastroenterology. 2024 Jan;166(1):202-2

[6] Scheinberg AR, Martin P, Turkeltaub JA. Terlipressin in the management of liver disease. Expert Opin Pharmacother. 2023 Sep-Dec;24(15):1665-1671.

[7] Glavaš M, Gitlin-Domagalska A, Dębowski D, Ptaszyńska N, Łęgowska A, Rolka K.Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides. Int J Mol Sci. 2022 Mar 12;23(6):3068.

[8] Liu D, Testro A, Majumdar A, Sinclair M. The current applications and future directions of terlipressin. Hepatol Commun. 2025 Apr 3;9(4):e0685. 

[9] Skvarce J, Bui A, Oro P, Sachar S, Harnegie MP, Kapoor A, Lindenmeyer CC, Siuba MT. Multisystem hemodynamic effects of terlipressin in cirrhosis: A scoping review. J Crit Care. 2025 Jun;87:155038.

[10] Vaishnav M, Biswas S, Shenoy A, Pathak P, Anand A, Swaroop S, Aggrawal A, Arora U, Elhence A, Jagannath S, Gunjan D, Kedia S, Mishra AK, Gamanagatti S, Nayak B, Garg P, Shalimar. Comparison of 1-day versus 3-day intravenous terlipressin in cirrhosis patients with variceal bleeding: A pilot randomised controlled trial. Aliment Pharmacol Ther. 2024 Mar;59(5):645-655.

[11] Roberts D, Best LM, Freeman SC, Sutton AJ, Cooper NJ, Arunan S, Begum T, Williams NR, Walshaw D, Milne EJ, Tapp M, Csenar M, Pavlov CS, Davidson BR, Tsochatzis E, Gurusamy KS. Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2021 Apr 10;4(4):CD013155.

[12] Ojeda-Yuren AS, Cerda-Reyes E, Herrero-Maceda MR, Castro-Narro G, Piano S. An Integrated Review of the Hepatorenal Syndrome. Ann Hepatol. 2021 May-Jun;22:100236. 

[13] Stajich GV, Ashworth L. Octreotide. Neonatal Netw. 2006 Sep-Oct;25(5):365-9. 

[14] Liu X, Guo X, Zhou H. Octreotide acetate combined with somatostatin upregulates miR-1291 and downregulates miR-331-3p in patients with cirrhosis and upper gastrointestinal bleeding. Am J Transl Res. 2021 Aug 15;13(8):9883-9891. 

[15] 严娅,陈俊旭,张铭光.奥曲肽联合凝血酶治疗肝硬化上消化道出血患者的疗效
[J].中国药物应用与监测,2025, 22(06):1053-1056.

[16] 武彦彤.探讨奥曲肽联合奥美拉唑治疗肝硬化合并上消化道出血的临床效果
[J].系统医学,2025,10(10):78-81.

[17] 辛胜,谭占超,郭欣欣.探究生长抑素与奥曲肽联合治疗肝硬化伴上消化道出血对患者凝血功能及肝功能指标的影响
[J].中外医疗,2024,43(25):103-106.

[18] 尚明岩.内镜下套扎术联合奥曲肽治疗食管胃底静脉曲张破裂出血患者的效果
[J].中国民康医学,2025,37(16): 30-32.

[19] 田寒. 大剂量奥曲肽治疗肝硬化合并上消化道出血的临床效果
[J]. 临床合理用药,2024,17(17):74-76. 

[20] Huaringa-Marcelo J, Huaman MR, Brañez-Condorena A, Villacorta-Landeo P, Pinto-Ruiz DF, Urday-Ipanaqué D, García-Gomero D, Montes-Teves P, Lozano Miranda A. Vasoactive Agents for the Management of Acute Variceal Bleeding: A Systematic Review and Meta-analysis. J Gastrointestin Liver Dis. 2021 Mar 13;30(1):110-121. 

[21] 田琳,刘咪,兰亚. 奥曲肽联合凝血酶治疗老年肝硬化合并上消化道出血的临床疗效及安全性观察
[J]. 贵州医药,2023,47(3):425-426. 

[22] 刘凯芹,闫瑾,马许辉,等. 奥曲肽联合特利加压素治疗肝硬化合并上消化道出血患者的临床疗效
[J]. 四川生理科学杂志,2025,47(1):44-46,125. 

[23] 邓臣前,孙娟.食管胃底静脉曲张出血的内镜诊断和治疗指南解读
[J].中国临床医生杂志,2023,51(07):775-780.

[24] 苗涛,幸福,周黎强,等.垂体后叶素联合生长抑素治疗肝硬化上消化道出血的有效性及安全性
[J].临床医学研究与实践,2024,9(33):75-78.

[25] 于金莲,魏晓华,薛挺.特利加压素联合生长抑素治疗肝硬化上消化道出血的疗效及安全性的Meta分析
[J].海南医学,2024,35(15):2222-2229.

[26] Fernández-Varo G, Jiménez W, Cable E, Ginès P, Harris G, Bukofzer S. Partial vasopressin 1a receptor agonism reduces portal hypertension and hyperaldosteronism and induces a powerful diuretic and natriuretic effect in rats with cirrhosis and ascites. Biomed Pharmacother. 2023 Sep;165:115116. 

[27] Castillo GM, Yao Y, Guerra RE, Jiang H, Nishimoto-Ashfield A, Lyubimov AV, Alfaro JF, Striker KA, Buynov N, Schwabl P, Bolotin EM. Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist. Biomed Pharmacother. 2024 Feb;171:116068.

[28] Perez-Campuzano V, Olivas P, Ferrusquía-Acosta J, Torres S, Borras R, Baiges A, Orts L, Vizcarra P, Falga MA, Codina J, Shalaby S, Ojeda A, Turon F, Hernández-Gea V, Cárdenas A, García-Pagán JC. Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension: a randomized, single-blind clinical trial. JHEP Rep. 2025 Jan 11;7(4):101325. 

[29] Arora V, Choudhary SP, Maiwall R, Vijayaraghavan R, Jindal A, Kumar G, Sarin SK. Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding. Hepatol Int. 2023 Feb;17(1):131-138. 

[30] Chapman B, Sinclair M, Majumdar A, Yu C, Widdop J, Hoermann R, Collins K, Terbah R, Tan K, Testro A. Real-World Experience of Home Continuous Terlipressin Infusion for Complications of Portal Hypertension. Am J Gastroenterol. 2025 Jun 11. 

[31] Garcia-Tsao G. Terlipressin and Intravenous Albumin in Advanced Cirrhosis - Friend and Foe. N Engl J Med. 2021 Mar 4;384(9):869-871. 

[32] Shang Y, Wang C, Lu H, Chai L, Xu W, Bernardi M, Qi X. Incidence and type of adverse events in patients with cirrhosis receiving terlipressin: A systematic review and meta-analysis. Hepatol Commun. 2024 Sep 18;8(10):e0526. 

[33] 闭玉华,徐辉,乔丽娟,等.卡维地洛、普萘洛尔治疗肝硬化食管静脉曲张出血患者再出血的临床研究
[J].中国临床药理学杂志,2024,40(18):2645-2649.

[34] 程洋,张峰,王曦旋,等.普萘洛尔与卡维地洛预防肝硬化患者并发食管胃静脉曲张破裂出血临床疗效比较
[J].实用肝脏病杂志,2023,26(02):254-257.

[35] 刘一锋,王小泽,杨丽.非选择性β受体阻滞剂在肝硬化治疗中的应用
[J].临床肝胆病杂志,2023,39(05):1178-1183.

[36] 程雅玮,朱晓龙,张春清.卡维地洛防治肝硬化门静脉高压研究进展
[J].中国临床医学,2024,31(03):374-378.

[37] 陈治莉,谢青,莫瑞东.新型非选择性β受体阻滞剂卡维地洛治疗门静脉高压症的研究进展
[J].肝脏,2024, 29(03):345-348.